Redwood Scientific Technologies, Inc.
Redwood Scientific Technologies, Inc. (RSCI) Stock Competitors & Peer Comparison
See (RSCI) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RSCI | $0.01 | +11000.00% | 1.9K | -0.56 | -$0.02 | N/A |
| IPSEY | $50.60 | +3.10% | 66.9B | 32.44 | $1.56 | +0.78% |
| MKGAF | $131.64 | -0.76% | 58.5B | 19.14 | $7.03 | +1.41% |
| MKKGY | $26.01 | +1.40% | 56.5B | 18.56 | $1.40 | +1.32% |
| TKPHF | $32.02 | -4.59% | 50.6B | 72.77 | $0.44 | +4.07% |
| HLNCF | $4.54 | -6.20% | 40.3B | 18.14 | $0.25 | +2.12% |
| SDZNY | $84.42 | +5.51% | 36.5B | 40.41 | $2.09 | +0.73% |
| TEVJF | $29.19 | +0.00% | 34B | 24.12 | $1.21 | N/A |
| TAIPY | $14.00 | +16.67% | 18.1B | 82.35 | $0.17 | N/A |
| ESALY | $61.51 | -2.11% | 17.6B | 20.54 | $3.00 | N/A |
Stock Comparison
RSCI vs IPSEY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, IPSEY has a market cap of 66.9B. Regarding current trading prices, RSCI is priced at $0.01, while IPSEY trades at $50.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas IPSEY's P/E ratio is 32.44. In terms of profitability, RSCI's ROE is +20.58%, compared to IPSEY's ROE of +0.10%. Regarding short-term risk, RSCI is more volatile compared to IPSEY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check IPSEY's competition here
RSCI vs MKGAF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, MKGAF has a market cap of 58.5B. Regarding current trading prices, RSCI is priced at $0.01, while MKGAF trades at $131.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas MKGAF's P/E ratio is 19.14. In terms of profitability, RSCI's ROE is +20.58%, compared to MKGAF's ROE of +0.09%. Regarding short-term risk, RSCI is more volatile compared to MKGAF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check MKGAF's competition here
RSCI vs MKKGY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, MKKGY has a market cap of 56.5B. Regarding current trading prices, RSCI is priced at $0.01, while MKKGY trades at $26.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas MKKGY's P/E ratio is 18.56. In terms of profitability, RSCI's ROE is +20.58%, compared to MKKGY's ROE of +0.09%. Regarding short-term risk, RSCI is more volatile compared to MKKGY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check MKKGY's competition here
RSCI vs TKPHF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, TKPHF has a market cap of 50.6B. Regarding current trading prices, RSCI is priced at $0.01, while TKPHF trades at $32.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas TKPHF's P/E ratio is 72.77. In terms of profitability, RSCI's ROE is +20.58%, compared to TKPHF's ROE of +0.02%. Regarding short-term risk, RSCI is more volatile compared to TKPHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check TKPHF's competition here
RSCI vs HLNCF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, HLNCF has a market cap of 40.3B. Regarding current trading prices, RSCI is priced at $0.01, while HLNCF trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas HLNCF's P/E ratio is 18.14. In terms of profitability, RSCI's ROE is +20.58%, compared to HLNCF's ROE of +0.06%. Regarding short-term risk, RSCI is more volatile compared to HLNCF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check HLNCF's competition here
RSCI vs SDZNY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, SDZNY has a market cap of 36.5B. Regarding current trading prices, RSCI is priced at $0.01, while SDZNY trades at $84.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas SDZNY's P/E ratio is 40.41. In terms of profitability, RSCI's ROE is +20.58%, compared to SDZNY's ROE of +0.08%. Regarding short-term risk, RSCI is more volatile compared to SDZNY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check SDZNY's competition here
RSCI vs TEVJF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, TEVJF has a market cap of 34B. Regarding current trading prices, RSCI is priced at $0.01, while TEVJF trades at $29.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas TEVJF's P/E ratio is 24.12. In terms of profitability, RSCI's ROE is +20.58%, compared to TEVJF's ROE of +0.21%. Regarding short-term risk, RSCI is more volatile compared to TEVJF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check TEVJF's competition here
RSCI vs TAIPY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, TAIPY has a market cap of 18.1B. Regarding current trading prices, RSCI is priced at $0.01, while TAIPY trades at $14.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas TAIPY's P/E ratio is 82.35. In terms of profitability, RSCI's ROE is +20.58%, compared to TAIPY's ROE of +0.02%. Regarding short-term risk, RSCI is more volatile compared to TAIPY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check TAIPY's competition here
RSCI vs ESALY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, ESALY has a market cap of 17.6B. Regarding current trading prices, RSCI is priced at $0.01, while ESALY trades at $61.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas ESALY's P/E ratio is 20.54. In terms of profitability, RSCI's ROE is +20.58%, compared to ESALY's ROE of +0.06%. Regarding short-term risk, RSCI is more volatile compared to ESALY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check ESALY's competition here
RSCI vs SGIOY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, SGIOY has a market cap of 16.8B. Regarding current trading prices, RSCI is priced at $0.01, while SGIOY trades at $9.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas SGIOY's P/E ratio is 15.41. In terms of profitability, RSCI's ROE is +20.58%, compared to SGIOY's ROE of +0.14%. Regarding short-term risk, RSCI is more volatile compared to SGIOY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check SGIOY's competition here
RSCI vs BIOVF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, BIOVF has a market cap of 16.4B. Regarding current trading prices, RSCI is priced at $0.01, while BIOVF trades at $47.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas BIOVF's P/E ratio is 169.55. In terms of profitability, RSCI's ROE is +20.58%, compared to BIOVF's ROE of +0.02%. Regarding short-term risk, RSCI is more volatile compared to BIOVF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check BIOVF's competition here
RSCI vs SGIOF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, SGIOF has a market cap of 16.3B. Regarding current trading prices, RSCI is priced at $0.01, while SGIOF trades at $19.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas SGIOF's P/E ratio is 14.92. In terms of profitability, RSCI's ROE is +20.58%, compared to SGIOF's ROE of +0.14%. Regarding short-term risk, RSCI is more volatile compared to SGIOF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check SGIOF's competition here
RSCI vs IPSEF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, IPSEF has a market cap of 9.4B. Regarding current trading prices, RSCI is priced at $0.01, while IPSEF trades at $113.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas IPSEF's P/E ratio is 18.07. In terms of profitability, RSCI's ROE is +20.58%, compared to IPSEF's ROE of +0.12%. Regarding short-term risk, RSCI is more volatile compared to IPSEF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check IPSEF's competition here
RSCI vs ESALF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, ESALF has a market cap of 8.5B. Regarding current trading prices, RSCI is priced at $0.01, while ESALF trades at $30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas ESALF's P/E ratio is 27.27. In terms of profitability, RSCI's ROE is +20.58%, compared to ESALF's ROE of +0.05%. Regarding short-term risk, RSCI is more volatile compared to ESALF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check ESALF's competition here
RSCI vs ESAIY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, ESAIY has a market cap of 8.4B. Regarding current trading prices, RSCI is priced at $0.01, while ESAIY trades at $7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas ESAIY's P/E ratio is 27.59. In terms of profitability, RSCI's ROE is +20.58%, compared to ESAIY's ROE of +0.05%. Regarding short-term risk, RSCI is more volatile compared to ESAIY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check ESAIY's competition here
RSCI vs SFOSF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, SFOSF has a market cap of 6.9B. Regarding current trading prices, RSCI is priced at $0.01, while SFOSF trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas SFOSF's P/E ratio is 13.68. In terms of profitability, RSCI's ROE is +20.58%, compared to SFOSF's ROE of +0.09%. Regarding short-term risk, RSCI is more volatile compared to SFOSF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check SFOSF's competition here
RSCI vs GZPHF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, GZPHF has a market cap of 6.2B. Regarding current trading prices, RSCI is priced at $0.01, while GZPHF trades at $2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas GZPHF's P/E ratio is 9.00. In terms of profitability, RSCI's ROE is +20.58%, compared to GZPHF's ROE of +0.08%. Regarding short-term risk, RSCI is more volatile compared to GZPHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check GZPHF's competition here
RSCI vs LVZPF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, LVZPF has a market cap of 6.1B. Regarding current trading prices, RSCI is priced at $0.01, while LVZPF trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas LVZPF's P/E ratio is 15.35. In terms of profitability, RSCI's ROE is +20.58%, compared to LVZPF's ROE of +0.14%. Regarding short-term risk, RSCI is more volatile compared to LVZPF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check LVZPF's competition here
RSCI vs HLBBF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, HLBBF has a market cap of 5.7B. Regarding current trading prices, RSCI is priced at $0.01, while HLBBF trades at $7.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas HLBBF's P/E ratio is 14.04. In terms of profitability, RSCI's ROE is +20.58%, compared to HLBBF's ROE of +0.13%. Regarding short-term risk, RSCI is more volatile compared to HLBBF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check HLBBF's competition here
RSCI vs HLUBF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, HLUBF has a market cap of 4.8B. Regarding current trading prices, RSCI is priced at $0.01, while HLUBF trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas HLUBF's P/E ratio is 9.64. In terms of profitability, RSCI's ROE is +20.58%, compared to HLUBF's ROE of +0.13%. Regarding short-term risk, RSCI is more volatile compared to HLUBF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check HLUBF's competition here
RSCI vs DNPUF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, DNPUF has a market cap of 4.5B. Regarding current trading prices, RSCI is priced at $0.01, while DNPUF trades at $11.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas DNPUF's P/E ratio is 4.59. In terms of profitability, RSCI's ROE is +20.58%, compared to DNPUF's ROE of +0.49%. Regarding short-term risk, RSCI is more volatile compared to DNPUF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check DNPUF's competition here
RSCI vs SGFEF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, SGFEF has a market cap of 4.4B. Regarding current trading prices, RSCI is priced at $0.01, while SGFEF trades at $100.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas SGFEF's P/E ratio is 20.37. In terms of profitability, RSCI's ROE is +20.58%, compared to SGFEF's ROE of +0.16%. Regarding short-term risk, RSCI is more volatile compared to SGFEF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check SGFEF's competition here
RSCI vs SMDPY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, SMDPY has a market cap of 4.4B. Regarding current trading prices, RSCI is priced at $0.01, while SMDPY trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas SMDPY's P/E ratio is 4.42. In terms of profitability, RSCI's ROE is +20.58%, compared to SMDPY's ROE of +0.49%. Regarding short-term risk, RSCI is more volatile compared to SMDPY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check SMDPY's competition here
RSCI vs HKMPF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, HKMPF has a market cap of 4.1B. Regarding current trading prices, RSCI is priced at $0.01, while HKMPF trades at $19.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas HKMPF's P/E ratio is 10.63. In terms of profitability, RSCI's ROE is +20.58%, compared to HKMPF's ROE of +0.16%. Regarding short-term risk, RSCI is more volatile compared to HKMPF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check HKMPF's competition here
RSCI vs HKMPY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, HKMPY has a market cap of 4.1B. Regarding current trading prices, RSCI is priced at $0.01, while HKMPY trades at $37.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas HKMPY's P/E ratio is 10.28. In terms of profitability, RSCI's ROE is +20.58%, compared to HKMPY's ROE of +0.16%. Regarding short-term risk, RSCI is more volatile compared to HKMPY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check HKMPY's competition here
RSCI vs APNHF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, APNHF has a market cap of 3.9B. Regarding current trading prices, RSCI is priced at $0.01, while APNHF trades at $8.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas APNHF's P/E ratio is -34.80. In terms of profitability, RSCI's ROE is +20.58%, compared to APNHF's ROE of -0.02%. Regarding short-term risk, RSCI is more volatile compared to APNHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check APNHF's competition here
RSCI vs APNHY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, APNHY has a market cap of 3.6B. Regarding current trading prices, RSCI is priced at $0.01, while APNHY trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas APNHY's P/E ratio is -32.16. In terms of profitability, RSCI's ROE is +20.58%, compared to APNHY's ROE of -0.02%. Regarding short-term risk, RSCI is more volatile compared to APNHY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check APNHY's competition here
RSCI vs HYPMY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, HYPMY has a market cap of 3.4B. Regarding current trading prices, RSCI is priced at $0.01, while HYPMY trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas HYPMY's P/E ratio is 9.25. In terms of profitability, RSCI's ROE is +20.58%, compared to HYPMY's ROE of +0.13%. Regarding short-term risk, RSCI is more volatile compared to HYPMY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check HYPMY's competition here
RSCI vs LBTSF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, LBTSF has a market cap of 3.3B. Regarding current trading prices, RSCI is priced at $0.01, while LBTSF trades at $15.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas LBTSF's P/E ratio is 59.04. In terms of profitability, RSCI's ROE is +20.58%, compared to LBTSF's ROE of +0.04%. Regarding short-term risk, RSCI is more volatile compared to LBTSF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check LBTSF's competition here
RSCI vs CHSYF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, CHSYF has a market cap of 3.3B. Regarding current trading prices, RSCI is priced at $0.01, while CHSYF trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas CHSYF's P/E ratio is 13.50. In terms of profitability, RSCI's ROE is +20.58%, compared to CHSYF's ROE of +0.09%. Regarding short-term risk, RSCI is more volatile compared to CHSYF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check CHSYF's competition here
RSCI vs INVVY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, INVVY has a market cap of 3B. Regarding current trading prices, RSCI is priced at $0.01, while INVVY trades at $21.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas INVVY's P/E ratio is -62.42. In terms of profitability, RSCI's ROE is +20.58%, compared to INVVY's ROE of -0.42%. Regarding short-term risk, RSCI is more volatile compared to INVVY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check INVVY's competition here
RSCI vs IZQVF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, IZQVF has a market cap of 2.9B. Regarding current trading prices, RSCI is priced at $0.01, while IZQVF trades at $20.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas IZQVF's P/E ratio is -56.68. In terms of profitability, RSCI's ROE is +20.58%, compared to IZQVF's ROE of -0.99%. Regarding short-term risk, RSCI is more volatile compared to IZQVF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check IZQVF's competition here
RSCI vs CURLF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, CURLF has a market cap of 2.7B. Regarding current trading prices, RSCI is priced at $0.01, while CURLF trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas CURLF's P/E ratio is -10.82. In terms of profitability, RSCI's ROE is +20.58%, compared to CURLF's ROE of -0.29%. Regarding short-term risk, RSCI is more volatile compared to CURLF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check CURLF's competition here
RSCI vs HMDCF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, HMDCF has a market cap of 2.4B. Regarding current trading prices, RSCI is priced at $0.01, while HMDCF trades at $2.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas HMDCF's P/E ratio is 5.32. In terms of profitability, RSCI's ROE is +20.58%, compared to HMDCF's ROE of +0.41%. Regarding short-term risk, RSCI is more volatile compared to HMDCF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check HMDCF's competition here
RSCI vs ULIHF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, ULIHF has a market cap of 2.3B. Regarding current trading prices, RSCI is priced at $0.01, while ULIHF trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas ULIHF's P/E ratio is 7.44. In terms of profitability, RSCI's ROE is +20.58%, compared to ULIHF's ROE of +0.13%. Regarding short-term risk, RSCI is more volatile compared to ULIHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check ULIHF's competition here
RSCI vs NPPNY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, NPPNY has a market cap of 2.2B. Regarding current trading prices, RSCI is priced at $0.01, while NPPNY trades at $8.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas NPPNY's P/E ratio is 10.72. In terms of profitability, RSCI's ROE is +20.58%, compared to NPPNY's ROE of +0.12%. Regarding short-term risk, RSCI is more volatile compared to NPPNY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check NPPNY's competition here
RSCI vs DMPHF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, DMPHF has a market cap of 2.1B. Regarding current trading prices, RSCI is priced at $0.01, while DMPHF trades at $39.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas DMPHF's P/E ratio is 17.90. In terms of profitability, RSCI's ROE is +20.58%, compared to DMPHF's ROE of +0.20%. Regarding short-term risk, RSCI is more volatile compared to DMPHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check DMPHF's competition here
RSCI vs NPNKF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, NPNKF has a market cap of 2.1B. Regarding current trading prices, RSCI is priced at $0.01, while NPNKF trades at $31.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas NPNKF's P/E ratio is 10.57. In terms of profitability, RSCI's ROE is +20.58%, compared to NPNKF's ROE of +0.11%. Regarding short-term risk, RSCI is more volatile compared to NPNKF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check NPNKF's competition here
RSCI vs HTSUF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, HTSUF has a market cap of 2B. Regarding current trading prices, RSCI is priced at $0.01, while HTSUF trades at $29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas HTSUF's P/E ratio is 16.76. In terms of profitability, RSCI's ROE is +20.58%, compared to HTSUF's ROE of +0.07%. Regarding short-term risk, RSCI is more volatile compared to HTSUF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check HTSUF's competition here
RSCI vs ARSUF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, ARSUF has a market cap of 1.9B. Regarding current trading prices, RSCI is priced at $0.01, while ARSUF trades at $26.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas ARSUF's P/E ratio is 18.30. In terms of profitability, RSCI's ROE is +20.58%, compared to ARSUF's ROE of +0.17%. Regarding short-term risk, RSCI is more volatile compared to ARSUF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check ARSUF's competition here
RSCI vs DUTV Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, DUTV has a market cap of 1.9B. Regarding current trading prices, RSCI is priced at $0.01, while DUTV trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas DUTV's P/E ratio is N/A. In terms of profitability, RSCI's ROE is +20.58%, compared to DUTV's ROE of -0.04%. Regarding short-term risk, RSCI is more volatile compared to DUTV. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check DUTV's competition here
RSCI vs GTBIF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, GTBIF has a market cap of 1.9B. Regarding current trading prices, RSCI is priced at $0.01, while GTBIF trades at $8.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas GTBIF's P/E ratio is 16.81. In terms of profitability, RSCI's ROE is +20.58%, compared to GTBIF's ROE of +0.06%. Regarding short-term risk, RSCI is more volatile compared to GTBIF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check GTBIF's competition here
RSCI vs TCNNF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, TCNNF has a market cap of 1.8B. Regarding current trading prices, RSCI is priced at $0.01, while TCNNF trades at $9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas TCNNF's P/E ratio is -16.55. In terms of profitability, RSCI's ROE is +20.58%, compared to TCNNF's ROE of -0.10%. Regarding short-term risk, RSCI is more volatile compared to TCNNF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check TCNNF's competition here
RSCI vs TSMRF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, TSMRF has a market cap of 1.7B. Regarding current trading prices, RSCI is priced at $0.01, while TSMRF trades at $23.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas TSMRF's P/E ratio is 10.04. In terms of profitability, RSCI's ROE is +20.58%, compared to TSMRF's ROE of +0.10%. Regarding short-term risk, RSCI is more volatile compared to TSMRF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check TSMRF's competition here
RSCI vs SHPHF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, SHPHF has a market cap of 1.7B. Regarding current trading prices, RSCI is priced at $0.01, while SHPHF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas SHPHF's P/E ratio is -6.22. In terms of profitability, RSCI's ROE is +20.58%, compared to SHPHF's ROE of +0.03%. Regarding short-term risk, RSCI is more volatile compared to SHPHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check SHPHF's competition here
RSCI vs MITPF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, MITPF has a market cap of 1.6B. Regarding current trading prices, RSCI is priced at $0.01, while MITPF trades at $23.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas MITPF's P/E ratio is -10.81. In terms of profitability, RSCI's ROE is +20.58%, compared to MITPF's ROE of +4.99%. Regarding short-term risk, RSCI is more volatile compared to MITPF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check MITPF's competition here
RSCI vs KARBF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, KARBF has a market cap of 1.5B. Regarding current trading prices, RSCI is priced at $0.01, while KARBF trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas KARBF's P/E ratio is 262.50. In terms of profitability, RSCI's ROE is +20.58%, compared to KARBF's ROE of N/A. Regarding short-term risk, RSCI is more volatile compared to KARBF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check KARBF's competition here
RSCI vs CASBF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, CASBF has a market cap of 1.3B. Regarding current trading prices, RSCI is priced at $0.01, while CASBF trades at $3.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas CASBF's P/E ratio is 193.00. In terms of profitability, RSCI's ROE is +20.58%, compared to CASBF's ROE of -0.00%. Regarding short-term risk, RSCI is more volatile compared to CASBF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check CASBF's competition here
RSCI vs SWGHF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, SWGHF has a market cap of 1.3B. Regarding current trading prices, RSCI is priced at $0.01, while SWGHF trades at $11.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas SWGHF's P/E ratio is 15.57. In terms of profitability, RSCI's ROE is +20.58%, compared to SWGHF's ROE of +0.05%. Regarding short-term risk, RSCI is more volatile compared to SWGHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check SWGHF's competition here
RSCI vs LJUIF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, LJUIF has a market cap of 1.2B. Regarding current trading prices, RSCI is priced at $0.01, while LJUIF trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas LJUIF's P/E ratio is 13.42. In terms of profitability, RSCI's ROE is +20.58%, compared to LJUIF's ROE of +0.06%. Regarding short-term risk, RSCI is more volatile compared to LJUIF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check LJUIF's competition here
RSCI vs BIOGY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, BIOGY has a market cap of 1.1B. Regarding current trading prices, RSCI is priced at $0.01, while BIOGY trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas BIOGY's P/E ratio is 31.43. In terms of profitability, RSCI's ROE is +20.58%, compared to BIOGY's ROE of +0.24%. Regarding short-term risk, RSCI is more volatile compared to BIOGY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check BIOGY's competition here
RSCI vs CHIZF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, CHIZF has a market cap of 1.1B. Regarding current trading prices, RSCI is priced at $0.01, while CHIZF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas CHIZF's P/E ratio is -21.89. In terms of profitability, RSCI's ROE is +20.58%, compared to CHIZF's ROE of -0.01%. Regarding short-term risk, RSCI is more volatile compared to CHIZF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check CHIZF's competition here
RSCI vs KSPHF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, KSPHF has a market cap of 1.1B. Regarding current trading prices, RSCI is priced at $0.01, while KSPHF trades at $25.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas KSPHF's P/E ratio is 11.77. In terms of profitability, RSCI's ROE is +20.58%, compared to KSPHF's ROE of +0.07%. Regarding short-term risk, RSCI is more volatile compared to KSPHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check KSPHF's competition here
RSCI vs GNMLF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, GNMLF has a market cap of 1.1B. Regarding current trading prices, RSCI is priced at $0.01, while GNMLF trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas GNMLF's P/E ratio is 12.00. In terms of profitability, RSCI's ROE is +20.58%, compared to GNMLF's ROE of +0.08%. Regarding short-term risk, RSCI is more volatile compared to GNMLF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check GNMLF's competition here
RSCI vs KKPCF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, KKPCF has a market cap of 984.6M. Regarding current trading prices, RSCI is priced at $0.01, while KKPCF trades at $26.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas KKPCF's P/E ratio is 288.89. In terms of profitability, RSCI's ROE is +20.58%, compared to KKPCF's ROE of -0.03%. Regarding short-term risk, RSCI is more volatile compared to KKPCF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check KKPCF's competition here
RSCI vs EVOTF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, EVOTF has a market cap of 930.6M. Regarding current trading prices, RSCI is priced at $0.01, while EVOTF trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas EVOTF's P/E ratio is -7.71. In terms of profitability, RSCI's ROE is +20.58%, compared to EVOTF's ROE of -0.12%. Regarding short-term risk, RSCI is more volatile compared to EVOTF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check EVOTF's competition here
RSCI vs TWAPF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, TWAPF has a market cap of 828.5M. Regarding current trading prices, RSCI is priced at $0.01, while TWAPF trades at $16.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas TWAPF's P/E ratio is 6.28. In terms of profitability, RSCI's ROE is +20.58%, compared to TWAPF's ROE of +0.12%. Regarding short-term risk, RSCI is more volatile compared to TWAPF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check TWAPF's competition here
RSCI vs CSWYF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, CSWYF has a market cap of 758.4M. Regarding current trading prices, RSCI is priced at $0.01, while CSWYF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas CSWYF's P/E ratio is 4.78. In terms of profitability, RSCI's ROE is +20.58%, compared to CSWYF's ROE of +0.12%. Regarding short-term risk, RSCI is more volatile compared to CSWYF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check CSWYF's competition here
RSCI vs GLASF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, GLASF has a market cap of 750.3M. Regarding current trading prices, RSCI is priced at $0.01, while GLASF trades at $9.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas GLASF's P/E ratio is -17.62. In terms of profitability, RSCI's ROE is +20.58%, compared to GLASF's ROE of -0.23%. Regarding short-term risk, RSCI is more volatile compared to GLASF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check GLASF's competition here
RSCI vs TRXPF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, TRXPF has a market cap of 690.7M. Regarding current trading prices, RSCI is priced at $0.01, while TRXPF trades at $24.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas TRXPF's P/E ratio is 25.86. In terms of profitability, RSCI's ROE is +20.58%, compared to TRXPF's ROE of +0.03%. Regarding short-term risk, RSCI is more volatile compared to TRXPF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check TRXPF's competition here
RSCI vs SHEZF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, SHEZF has a market cap of 689M. Regarding current trading prices, RSCI is priced at $0.01, while SHEZF trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas SHEZF's P/E ratio is -23.48. In terms of profitability, RSCI's ROE is +20.58%, compared to SHEZF's ROE of +0.03%. Regarding short-term risk, RSCI is more volatile compared to SHEZF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check SHEZF's competition here
RSCI vs YIHCF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, YIHCF has a market cap of 643.1M. Regarding current trading prices, RSCI is priced at $0.01, while YIHCF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas YIHCF's P/E ratio is -5.00. In terms of profitability, RSCI's ROE is +20.58%, compared to YIHCF's ROE of +0.06%. Regarding short-term risk, RSCI is more volatile compared to YIHCF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check YIHCF's competition here
RSCI vs AIHLF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, AIHLF has a market cap of 624.3M. Regarding current trading prices, RSCI is priced at $0.01, while AIHLF trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas AIHLF's P/E ratio is 10.94. In terms of profitability, RSCI's ROE is +20.58%, compared to AIHLF's ROE of +0.15%. Regarding short-term risk, RSCI is more volatile compared to AIHLF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check AIHLF's competition here
RSCI vs TRSSF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, TRSSF has a market cap of 601.9M. Regarding current trading prices, RSCI is priced at $0.01, while TRSSF trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas TRSSF's P/E ratio is -1.32. In terms of profitability, RSCI's ROE is +20.58%, compared to TRSSF's ROE of -0.68%. Regarding short-term risk, RSCI is more volatile compared to TRSSF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check TRSSF's competition here
RSCI vs AGYTF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, AGYTF has a market cap of 554.6M. Regarding current trading prices, RSCI is priced at $0.01, while AGYTF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas AGYTF's P/E ratio is -11.00. In terms of profitability, RSCI's ROE is +20.58%, compared to AGYTF's ROE of +2.84%. Regarding short-term risk, RSCI is more volatile compared to AGYTF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check AGYTF's competition here
RSCI vs PKBFF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, PKBFF has a market cap of 544.7M. Regarding current trading prices, RSCI is priced at $0.01, while PKBFF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas PKBFF's P/E ratio is N/A. In terms of profitability, RSCI's ROE is +20.58%, compared to PKBFF's ROE of +7.96%. Regarding short-term risk, RSCI is more volatile compared to PKBFF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check PKBFF's competition here
RSCI vs KHTRF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, KHTRF has a market cap of 529.6M. Regarding current trading prices, RSCI is priced at $0.01, while KHTRF trades at $5.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas KHTRF's P/E ratio is -135.05. In terms of profitability, RSCI's ROE is +20.58%, compared to KHTRF's ROE of -0.01%. Regarding short-term risk, RSCI is more volatile compared to KHTRF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check KHTRF's competition here
RSCI vs CCHWF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, CCHWF has a market cap of 521.3M. Regarding current trading prices, RSCI is priced at $0.01, while CCHWF trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas CCHWF's P/E ratio is -1.12. In terms of profitability, RSCI's ROE is +20.58%, compared to CCHWF's ROE of +0.42%. Regarding short-term risk, RSCI is more volatile compared to CCHWF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check CCHWF's competition here
RSCI vs BOIRF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, BOIRF has a market cap of 520.9M. Regarding current trading prices, RSCI is priced at $0.01, while BOIRF trades at $30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas BOIRF's P/E ratio is 22.73. In terms of profitability, RSCI's ROE is +20.58%, compared to BOIRF's ROE of +0.05%. Regarding short-term risk, RSCI is more volatile compared to BOIRF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check BOIRF's competition here
RSCI vs VRNOF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, VRNOF has a market cap of 470.4M. Regarding current trading prices, RSCI is priced at $0.01, while VRNOF trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas VRNOF's P/E ratio is -1.31. In terms of profitability, RSCI's ROE is +20.58%, compared to VRNOF's ROE of -0.31%. Regarding short-term risk, RSCI is more volatile compared to VRNOF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check VRNOF's competition here
RSCI vs PEXXF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, PEXXF has a market cap of 463.1M. Regarding current trading prices, RSCI is priced at $0.01, while PEXXF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas PEXXF's P/E ratio is 9.00. In terms of profitability, RSCI's ROE is +20.58%, compared to PEXXF's ROE of N/A. Regarding short-term risk, RSCI is more volatile compared to PEXXF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check PEXXF's competition here
RSCI vs HUMDF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, HUMDF has a market cap of 430.9M. Regarding current trading prices, RSCI is priced at $0.01, while HUMDF trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas HUMDF's P/E ratio is 2.70. In terms of profitability, RSCI's ROE is +20.58%, compared to HUMDF's ROE of +1.07%. Regarding short-term risk, RSCI is more volatile compared to HUMDF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check HUMDF's competition here
RSCI vs NIKA Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, NIKA has a market cap of 421.1M. Regarding current trading prices, RSCI is priced at $0.01, while NIKA trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas NIKA's P/E ratio is N/A. In terms of profitability, RSCI's ROE is +20.58%, compared to NIKA's ROE of +0.29%. Regarding short-term risk, RSCI is more volatile compared to NIKA. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check NIKA's competition here
RSCI vs SWDCF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, SWDCF has a market cap of 399.6M. Regarding current trading prices, RSCI is priced at $0.01, while SWDCF trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas SWDCF's P/E ratio is 83.33. In terms of profitability, RSCI's ROE is +20.58%, compared to SWDCF's ROE of +0.01%. Regarding short-term risk, RSCI is more volatile compared to SWDCF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check SWDCF's competition here
RSCI vs ELTP Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, ELTP has a market cap of 378M. Regarding current trading prices, RSCI is priced at $0.01, while ELTP trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas ELTP's P/E ratio is 8.77. In terms of profitability, RSCI's ROE is +20.58%, compared to ELTP's ROE of +0.71%. Regarding short-term risk, RSCI is more volatile compared to ELTP. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check ELTP's competition here
RSCI vs CRLBF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, CRLBF has a market cap of 374.1M. Regarding current trading prices, RSCI is priced at $0.01, while CRLBF trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas CRLBF's P/E ratio is -2.87. In terms of profitability, RSCI's ROE is +20.58%, compared to CRLBF's ROE of -0.33%. Regarding short-term risk, RSCI is more volatile compared to CRLBF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check CRLBF's competition here
RSCI vs CPHRF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, CPHRF has a market cap of 333.7M. Regarding current trading prices, RSCI is priced at $0.01, while CPHRF trades at $13.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas CPHRF's P/E ratio is 12.57. In terms of profitability, RSCI's ROE is +20.58%, compared to CPHRF's ROE of +0.24%. Regarding short-term risk, RSCI is more volatile compared to CPHRF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check CPHRF's competition here
RSCI vs BHCCF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, BHCCF has a market cap of 225.1M. Regarding current trading prices, RSCI is priced at $0.01, while BHCCF trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas BHCCF's P/E ratio is -4.57. In terms of profitability, RSCI's ROE is +20.58%, compared to BHCCF's ROE of +0.29%. Regarding short-term risk, RSCI is more volatile compared to BHCCF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check BHCCF's competition here
RSCI vs PLNHF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, PLNHF has a market cap of 202M. Regarding current trading prices, RSCI is priced at $0.01, while PLNHF trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas PLNHF's P/E ratio is -3.50. In terms of profitability, RSCI's ROE is +20.58%, compared to PLNHF's ROE of +659479.06%. Regarding short-term risk, RSCI is more volatile compared to PLNHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check PLNHF's competition here
RSCI vs PHCUF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, PHCUF has a market cap of 188.1M. Regarding current trading prices, RSCI is priced at $0.01, while PHCUF trades at $7.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas PHCUF's P/E ratio is -707.00. In terms of profitability, RSCI's ROE is +20.58%, compared to PHCUF's ROE of -0.00%. Regarding short-term risk, RSCI is more volatile compared to PHCUF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check PHCUF's competition here
RSCI vs CBWTF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, CBWTF has a market cap of 139.2M. Regarding current trading prices, RSCI is priced at $0.01, while CBWTF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas CBWTF's P/E ratio is 4.96. In terms of profitability, RSCI's ROE is +20.58%, compared to CBWTF's ROE of +0.23%. Regarding short-term risk, RSCI is more volatile compared to CBWTF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check CBWTF's competition here
RSCI vs COPHF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, COPHF has a market cap of 131.7M. Regarding current trading prices, RSCI is priced at $0.01, while COPHF trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas COPHF's P/E ratio is -0.02. In terms of profitability, RSCI's ROE is +20.58%, compared to COPHF's ROE of -5.75%. Regarding short-term risk, RSCI is more volatile compared to COPHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check COPHF's competition here
RSCI vs LOVFF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, LOVFF has a market cap of 128.4M. Regarding current trading prices, RSCI is priced at $0.01, while LOVFF trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas LOVFF's P/E ratio is 16.25. In terms of profitability, RSCI's ROE is +20.58%, compared to LOVFF's ROE of +0.09%. Regarding short-term risk, RSCI is more volatile compared to LOVFF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check LOVFF's competition here
RSCI vs NWPN Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, NWPN has a market cap of 123.7M. Regarding current trading prices, RSCI is priced at $0.01, while NWPN trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas NWPN's P/E ratio is -0.04. In terms of profitability, RSCI's ROE is +20.58%, compared to NWPN's ROE of +0.13%. Regarding short-term risk, RSCI is less volatile compared to NWPN. This indicates potentially lower risk in terms of short-term price fluctuations for RSCI.Check NWPN's competition here
RSCI vs BIOYF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, BIOYF has a market cap of 122.2M. Regarding current trading prices, RSCI is priced at $0.01, while BIOYF trades at $10.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas BIOYF's P/E ratio is 18.65. In terms of profitability, RSCI's ROE is +20.58%, compared to BIOYF's ROE of +0.23%. Regarding short-term risk, RSCI is more volatile compared to BIOYF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check BIOYF's competition here
RSCI vs SHIEF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, SHIEF has a market cap of 120.7M. Regarding current trading prices, RSCI is priced at $0.01, while SHIEF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas SHIEF's P/E ratio is -5.65. In terms of profitability, RSCI's ROE is +20.58%, compared to SHIEF's ROE of +1.01%. Regarding short-term risk, RSCI is more volatile compared to SHIEF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check SHIEF's competition here
RSCI vs AAWH Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, AAWH has a market cap of 113.2M. Regarding current trading prices, RSCI is priced at $0.01, while AAWH trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas AAWH's P/E ratio is -0.97. In terms of profitability, RSCI's ROE is +20.58%, compared to AAWH's ROE of -14.10%. Regarding short-term risk, RSCI is more volatile compared to AAWH. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check AAWH's competition here
RSCI vs LPCUF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, LPCUF has a market cap of 112.1M. Regarding current trading prices, RSCI is priced at $0.01, while LPCUF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas LPCUF's P/E ratio is 9.51. In terms of profitability, RSCI's ROE is +20.58%, compared to LPCUF's ROE of +0.06%. Regarding short-term risk, RSCI is more volatile compared to LPCUF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check LPCUF's competition here
RSCI vs CNVCF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, CNVCF has a market cap of 109.2M. Regarding current trading prices, RSCI is priced at $0.01, while CNVCF trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas CNVCF's P/E ratio is -5.00. In terms of profitability, RSCI's ROE is +20.58%, compared to CNVCF's ROE of +1.21%. Regarding short-term risk, RSCI is more volatile compared to CNVCF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check CNVCF's competition here
RSCI vs HLTRF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, HLTRF has a market cap of 107.6M. Regarding current trading prices, RSCI is priced at $0.01, while HLTRF trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas HLTRF's P/E ratio is -8.82. In terms of profitability, RSCI's ROE is +20.58%, compared to HLTRF's ROE of -0.19%. Regarding short-term risk, RSCI is more volatile compared to HLTRF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check HLTRF's competition here
RSCI vs JUSHF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, JUSHF has a market cap of 99.8M. Regarding current trading prices, RSCI is priced at $0.01, while JUSHF trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas JUSHF's P/E ratio is -1.43. In terms of profitability, RSCI's ROE is +20.58%, compared to JUSHF's ROE of +0.76%. Regarding short-term risk, RSCI is more volatile compared to JUSHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check JUSHF's competition here
RSCI vs MEDXF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, MEDXF has a market cap of 92.7M. Regarding current trading prices, RSCI is priced at $0.01, while MEDXF trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas MEDXF's P/E ratio is -143.50. In terms of profitability, RSCI's ROE is +20.58%, compared to MEDXF's ROE of -0.01%. Regarding short-term risk, RSCI is more volatile compared to MEDXF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check MEDXF's competition here
RSCI vs GRUSF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, GRUSF has a market cap of 92.5M. Regarding current trading prices, RSCI is priced at $0.01, while GRUSF trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas GRUSF's P/E ratio is 37.00. In terms of profitability, RSCI's ROE is +20.58%, compared to GRUSF's ROE of +0.00%. Regarding short-term risk, RSCI is more volatile compared to GRUSF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check GRUSF's competition here
RSCI vs CWBHF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, CWBHF has a market cap of 78M. Regarding current trading prices, RSCI is priced at $0.01, while CWBHF trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas CWBHF's P/E ratio is -2.56. In terms of profitability, RSCI's ROE is +20.58%, compared to CWBHF's ROE of -2.75%. Regarding short-term risk, RSCI is more volatile compared to CWBHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check CWBHF's competition here
RSCI vs ABSCF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, ABSCF has a market cap of 74.1M. Regarding current trading prices, RSCI is priced at $0.01, while ABSCF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas ABSCF's P/E ratio is -6.22. In terms of profitability, RSCI's ROE is +20.58%, compared to ABSCF's ROE of +0.33%. Regarding short-term risk, RSCI is more volatile compared to ABSCF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check ABSCF's competition here
RSCI vs ORXOF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, ORXOF has a market cap of 73.8M. Regarding current trading prices, RSCI is priced at $0.01, while ORXOF trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas ORXOF's P/E ratio is -1.62. In terms of profitability, RSCI's ROE is +20.58%, compared to ORXOF's ROE of -2.28%. Regarding short-term risk, RSCI is more volatile compared to ORXOF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check ORXOF's competition here
RSCI vs EOFBY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, EOFBY has a market cap of 73.7M. Regarding current trading prices, RSCI is priced at $0.01, while EOFBY trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas EOFBY's P/E ratio is -7.67. In terms of profitability, RSCI's ROE is +20.58%, compared to EOFBY's ROE of -0.77%. Regarding short-term risk, RSCI is more volatile compared to EOFBY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check EOFBY's competition here
RSCI vs ORXOY Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, ORXOY has a market cap of 71.8M. Regarding current trading prices, RSCI is priced at $0.01, while ORXOY trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas ORXOY's P/E ratio is -1.64. In terms of profitability, RSCI's ROE is +20.58%, compared to ORXOY's ROE of -2.28%. Regarding short-term risk, RSCI is more volatile compared to ORXOY. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check ORXOY's competition here
RSCI vs GDNSF Comparison May 2026
RSCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSCI stands at 1.9K. In comparison, GDNSF has a market cap of 61M. Regarding current trading prices, RSCI is priced at $0.01, while GDNSF trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSCI currently has a P/E ratio of -0.56, whereas GDNSF's P/E ratio is -2.66. In terms of profitability, RSCI's ROE is +20.58%, compared to GDNSF's ROE of -0.69%. Regarding short-term risk, RSCI is more volatile compared to GDNSF. This indicates potentially higher risk in terms of short-term price fluctuations for RSCI.Check GDNSF's competition here